Drug Patents owned by Acacia

1. Drug name - BARHEMSYS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10525033 ACACIA Use of amisulpride as an anti-emetic Mar, 2031

(8 years from now)

US9545426 ACACIA Use of amisulpride as an anti-emetic Mar, 2031

(8 years from now)

US9084765 ACACIA Use of amisulpride as an anti-emetic Mar, 2031

(8 years from now)

US9889118 ACACIA Use of amisulpride as an anti-emetic Mar, 2031

(8 years from now)

Drugs and Companies using AMISULPRIDE ingredient

Treatment: Prevention of post-operative nausea and vomiting; treatment of post-operative nausea and vomiting; Treatment of post-operative nausea and vomiting; prevention of post-operative nausea and vomiting

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
5MG/2ML (2.5MG/ML) SOLUTION;INTRAVENOUS Prescription
10MG/4ML (2.5MG/ML) SOLUTION;INTRAVENOUS Prescription

2. Drug name - BYFAVO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9777007 ACACIA Short-acting benzodiazepine salts and their polymorphic forms Jul, 2027

(4 years from now)

US10472365 ACACIA Short-acting benzodiazepine salts and their polymorphic forms Jul, 2027

(4 years from now)

US9914738 ACACIA Short-acting benzodiazepine salts and their polymorphic forms Jul, 2027

(4 years from now)

US9827251 ACACIA Dosing regimen for sedation with CNS 7056 (remimazolam) Nov, 2031

(9 years from now)

US10722522 ACACIA Dosing regimen for sedation with CNS 7056 (remimazolam) Nov, 2031

(9 years from now)

US9737547 ACACIA Dosing regimen for sedation with CNS 7056 (Remimazolam) Nov, 2031

(9 years from now)

US10342800 ACACIA Dosing regimen for sedation with CNS 7056 (Remimazolam) Nov, 2031

(9 years from now)

US10052334 ACACIA Dosing regimen for sedation with CNS 7056 (remimazolam) Nov, 2031

(9 years from now)

US10195210 ACACIA Dosing regimen for sedation with CNS 7056 (Remimazolam) Nov, 2031

(9 years from now)

US9561236 ACACIA Dosing regimen for sedation with CNS 7056 (Remimazolam) Apr, 2033

(10 years from now)

Drugs and Companies using REMIMAZOLAM BESYLATE ingredient

Treatment: Use of remimazolam for induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE/VIAL POWDER;INTRAVENOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.